Last reviewed · How we verify

Bravavir (SORIVUDINE)

FDA-approved withdrawn Small molecule Under review Quality 10/100

Bravavir (generic name: SORIVUDINE) is a sorivudine drug. It is currently FDA-approved.

Bravavir, also known as sorivudine, is a small molecule inhibitor of the DNA polymerase catalytic subunit. It has been studied in clinical trials for various conditions, including Herpes Zoster, Postherpetic Neuralgia, HIV Infections, Chickenpox, and Metastatic Breast Cancer.

At a glance

Generic nameSORIVUDINE
Drug classsorivudine
TargetThymidine kinase, mitochondrial, Deoxynucleoside kinase, Thymidine kinase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bravavir

What is Bravavir?

Bravavir (SORIVUDINE) is a sorivudine drug.

What is the generic name of Bravavir?

SORIVUDINE is the generic (nonproprietary) name of Bravavir.

What drug class is Bravavir in?

Bravavir belongs to the sorivudine class. See all sorivudine drugs at /class/sorivudine.

What development phase is Bravavir in?

Bravavir is FDA-approved (marketed).

What does Bravavir target?

Bravavir targets Thymidine kinase, mitochondrial, Deoxynucleoside kinase, Thymidine kinase and is a sorivudine.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing